Impact of Propionic Acid on Regulatory T Cell Function in Healthy Adults ( Pro-Health)
Condition(s) studied
Investigational drug(s) / intervention(s)
Sodium propionate: The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
Placebo: The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
Study summary
Pro-Health is a single-center, double-blind, randomized and placebo-controlled intervention study in healthy adults. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in healhty adults.
Eligibility
Primary outcome measure(s)
- Change in count of regulatory T-cells from baseline to week 4 — Baseline visit (week 0) in comparison to week 4
Analysis of Treg counts in whole blood (absolute quantification) and peripheral blood
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin | Berlin | State of Berlin |
More Charite University, Berlin, Germany trials in Germany
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06198374 on ClinicalTrials.gov ↗ ← All trials in Germany